Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$21.89 -10.03%

-$3.24 today

Market cap
$3.71B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 2.75M

Average 3.67M

TNGX EBITDA Margin

EBITDA as a percentage of revenue.

Tango Therapeutics, Inc.NASDAQ: TNGX

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin not reported for Q3 FY2026

Over 3 fiscal years it widened by 269.3 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 8 analysts of -2792.6% for the fiscal year ending Dec 2026, down from -159.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
—— QoQ
Last fiscal yearDec 2025
-159.2%+144.1 pp YoY
LTMSep 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+144.1 pp-2633.4 pp-2777.6 pp
3 years+269.3 pp-367.0 pp-636.3 pp
5 years+179.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-159.2%
Year-over-year change
+144.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How TNGX compares with its peers on the latest reported figures

  • TNGX's FY2025 EBITDA Margin of -159.2% is the 4th highest of the 8 companies compared; the peer median is -257.0%.
  • Its year-over-year change of +144.1 pp is the 6th highest of 8, against a peer median of +927.4 pp.
  • Over three fiscal years its change of +269.3 pp compares with a peer median of +147.4 pp.
TNGX Competitors Peer median
EBITDA Margin for TNGX and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202646.0% +315.4 pp+147.4 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-60.1% +4260.2 pp+61.2 pp
NUVBNuvation Bio Inc.LTM Jun 2026-74.8% +1326.6 pp—
TNGXTango Therapeutics, Inc.FY2025-159.2% +144.1 pp+269.3 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-257.0% +77.3 pp+319.4 pp
CCCCC4 Therapeutics, Inc.LTM Mar 2026-287.9% -44.6 pp+113.4 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-455.3% +1345.3 pp—
RLAYRelay Therapeutics, Inc.LTM Jun 2026-2742.3% +927.4 pp+20440.0 pp
RVMDRevolution Medicines, Inc.FY2025— ——
ERASErasca, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding TNGX) -257.0%+927.4 pp+147.4 pp

Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.04M24.86M36.53M42.07M62.38M
Cost of Revenue00002.28M
Gross Profit37.04M24.86M36.53M42.07M60.1M
Gross Margin100.0%100.0%100.0%100.0%96.3%
Research & Development77.64M105.91M115.2M143.92M132.17M
Selling, General & Admin17.6M30.03M35.5M43.75M41.51M
Operating Expenses95.23M135.93M150.7M187.66M171.39M
Depreciation & Amortization897K1.61M2.42M2.5M2.28M
EBITDA(57.05M)(106.51M)(99.2M)(127.6M)(99.31M)
EBITDA Margin-154.0%-428.5%-271.6%-303.3%-159.2%
Operating Income(58.19M)(111.07M)(114.17M)(145.6M)(111.29M)
Operating Margin-157.1%-446.8%-312.6%-346.1%-178.4%
Interest Income495K1.46M6.62M7.89M5.63M
Interest Expense00000
Other Income / Expenses247K2.95M12.56M15.5M9.7M
Income Before Tax(57.94M)(108.12M)(101.61M)(130.09M)(101.59M)
Pre-Tax Margin-156.4%-434.9%-278.2%-309.2%-162.8%
Income Tax Expense292K54K134K208K4K
Net Income(58.24M)(108.18M)(101.74M)(130.3M)(101.59M)
Net Margin-157.2%-435.1%-278.5%-309.7%-162.9%
EPS (Basic)(0.94)(1.23)(1.08)(1.19)(0.87)
EPS (Diluted)(0.94)(1.23)(1.08)(1.19)(0.87)
Weighted Avg Shares62.11M87.82M94.57M109.23M116.17M
Weighted Avg Shares (Diluted)62.11M87.82M94.57M109.23M116.17M

Tango Therapeutics, Inc.

NASDAQ:TNGX

Intrinsic Alpha fair value

Locked

Current Price

$21.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.